

New Products - Nesina Met

Nesina Met (**alogliptin/ metformin hydrochloride**) contains two oral antihyperglycaemic drugs: alogliptin (as benzoate), a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class. Nesina Met is indicated as an adjunct to diet and exercise to improve glycaemic control in type 2 diabetes: patients inadequately controlled with metformin alone; patients currently treated with alogliptin + metformin combination (separate tablets; fixed dose combination not for initial treatment) and as a combination with thiazolidinedione (TZD) or insulin (inadequately controlled by dual therapy). It is contraindicated in the following conditions. Renal disease or dysfunction (serum creatinine ≥ 135 micromol/L (males), ≥ 110 micromol/L (females), CrCl less than 60 mL/min) including those caused by CV collapse (shock), acute MI, septicemia; acute or chronic metabolic acidosis including diabetic ketoacidosis, diabetic coma, pre-coma; radiological studies involving intravascular iodinated contrast material administration (temporarily discontinue prior to or at time of procedure; withhold for 48 hrs post-procedure, may reintroduce if renal function normal). Nesina Met is available in packs of 56's as alogliptin (as benzoate)/metformin hydrochloride 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.